Daratumumab/lenalidomide/ dexamethasone for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation

• Autores: Raquel Claramunt García, Alberto Soria Martín, Andres Sanchez Ruiz
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 23, Nº. 3, 2021, págs. 193-196
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The Daratumumab/Lenalidomide/Dexamethasone regimen has recently been approved by the European Medicines Agency for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation. This combination has been studied in the pivotal phase III MAIA trial where participants were assigned to receive Daratumumab/Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone. The progression free survival result favors treatment group, with a HR: 0.56 (95% CI: 0.44-0.71; P <0.0001). According to metanalysis and indirect comparisons, Daratumumab/Lenalidomide/Dexamethasone is comparable in efficacy and safety to existing alternatives for the proposed indication, but it does not provide any improvement in the cost-effectiveness profile